0000950123-20-008777.txt : 20200814 0000950123-20-008777.hdr.sgml : 20200814 20200814080514 ACCESSION NUMBER: 0000950123-20-008777 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200814 DATE AS OF CHANGE: 20200814 EFFECTIVENESS DATE: 20200814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 201101435 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml 13F-HR LIVE 0001703031 XXXXXXXX 06-30-2020 06-30-2020 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P. and (ii) the general partner of BC SW, LP. The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on May 28, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of June 30, 2020, such persons held an aggregate of 8,525,000 shares of DVAX common stock. The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 30, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of June 30, 2020, such persons held an aggregate of 4,571,139 shares of SVRA common stock. The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 9, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise or conversion. As of June 30, 2020, such persons held an aggregate of 1,250,000 shares of XFOR common stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 08-14-2020 3 15 954774 false 1 28-18476 Bain Capital Life Sciences Partners, LP 2 28-18478 Bain Capital Life Sciences Fund, LP 3 28-20270 BC SW, LP INFORMATION TABLE 2 773.xml INFORMATION TABLE FOR FORM 13F DICERNA PHARMACEUTICALS INC COM 253031108 103638 4080237 SH SOLE 4080237 0 0 MARINUS PHARMACEUTICALS INC COM 56854Q101 14540 5724235 SH SOLE 5724235 0 0 REPLIMUNE GROUP INC COM 76029N106 53741 2162598 SH SOLE 2162598 0 0 SOLID BIOSCIENCES INC COM 83422E105 11343 3871164 SH SOLE 3871164 0 0 APTINYX INC COM 03836N103 23179 5558425 SH SOLE 5558425 0 0 SPRINGWORKS THERAPEUTICS INC COM 85205L107 305815 7281307 SH SOLE 7281307 0 0 DYNAVAX TECHNOLOGIES CORP. COM 268158201 96646 10895773 SH SOLE 10895773 0 0 CONSTELLATION PHARMACEUTICALS INC. COM 210373106 42070 1400000 SH SOLE 1400000 0 0 X4 PHARMACEUTICALS INC COM 98420X103 15364 1648485 SH SOLE 1648485 0 0 SAVARA INC COM 805111101 22976 5128593 SH SOLE 5128593 0 0 ARCUTIS BIOTHERAPEUTICS, INC. COM 03969K108 120334 3979292 SH SOLE 3979292 0 0 MERSANA THERAPEUTICS, INC. COM 59045L106 80629 3445667 SH SOLE 3445667 0 0 CRINETICS PHARMACEUTICALS, INC. COM 22663K107 18771 1071428 SH SOLE 1071428 0 0 SAGE THERAPEUTICS, INC. COM 78667J108 20753 499100 SH SOLE 499100 0 0 AEGLEA BIOTHERAPEUTICS, INC. COM 00773J103 24975 2700000 SH SOLE 2700000 0 0